https://www.biopharmawatch.com/news/ZJYL/jin-medical-global-expo-participation-2026 BiopharmaWatch en 2026-11-02T14:20:00.000Z Jin Medical Showcases Innovation Across Four Global Industry Expos: Lightweight Rehabilitation Assistive Line Draws Broad Market Attention https://www.biopharmawatch.com/news/SUPN/supernus-indivior-complete-merger-creating-diversified-cns-biopharmaceutical-leader BiopharmaWatch en 2026-11-02T14:18:00.000Z Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader https://www.biopharmawatch.com/news/TRLV/trulieve-receives-dea-registrations-medical-marijuana BiopharmaWatch en 2026-11-02T14:17:00.000Z Trulieve Receives DEA Registrations for State-Licensed Medical Marijuana Operations https://www.biopharmawatch.com/news/HCTI/healthcare-triangle-expands-into-indonesia BiopharmaWatch en 2026-11-02T14:15:00.000Z Healthcare Triangle Expands into Indonesia; Identifying USD 45 Million Opportunity https://www.biopharmawatch.com/news/EIKN/eikon-therapeutics-investor-conferences-november-2026 BiopharmaWatch en 2026-11-02T14:15:00.000Z Eikon Therapeutics to Participate in Multiple Investor Conferences in November https://www.biopharmawatch.com/news/JAGX/napo-pharmaceuticals-panel-discussion-dubai BiopharmaWatch en 2026-11-02T14:00:00.000Z CSO of Napo Pharmaceuticals, a Jaguar Health Family Company, and Clinical Investigators Evaluating Crofelemer Conduct Panel Discussion at Pediatric Gastroenterology Conference in Dubai (UAE) https://www.biopharmawatch.com/news/SBC/sbc-medical-forms-alliance-atomicsoftware BiopharmaWatch en 2026-11-02T14:00:00.000Z SBC Medical Forms Capital and Business Alliance with AtomicSoftware, Provider of the medicalforce Clinic Management Platform Used by 800+ Clinics in Japan https://www.biopharmawatch.com/news/AMLX/amylyx-pharmaceuticals-third-quarter-2026-results BiopharmaWatch en 2026-11-02T14:00:00.000Z Amylyx Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026 https://www.biopharmawatch.com/news/KEQU/kewaunee-acquires-nycom-lab-dealer BiopharmaWatch en 2026-11-02T14:00:00.000Z Kewaunee Scientific Announces Agreement to Acquire Nycom, Inc. https://www.biopharmawatch.com/news/TXG/10x-genomics-launches-sentira-single-cell-ai-analysis BiopharmaWatch en 2026-11-02T14:00:00.000Z 10x Genomics Launches Sentira Single Cell, A New Agentic AI Experience for Chromium Analysis https://www.biopharmawatch.com/news/CHE/chemed-corporation-ubs-2026-healthcare-conference BiopharmaWatch en 2026-11-02T14:00:00.000Z Chemed Corporation to Present at the UBS 2026 Global Healthcare Conference https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-participate-upcoming-november-investor-events BiopharmaWatch en 2026-11-02T14:00:00.000Z Compass Therapeutics to Participate in Upcoming November Investor Events https://www.biopharmawatch.com/news/BIVI/biovie-late-breaking-presentation-bezisterim-long-covid BiopharmaWatch en 2026-11-02T14:00:00.000Z BioVie Selected for Late-Breaking Oral Presentation of Bezisterim Long COVID Data at the 4th Long COVID International Conference 2026 https://www.biopharmawatch.com/news/STXS/robocath-next-gen-robotic-system-tct-2026 BiopharmaWatch en 2026-11-02T13:48:00.000Z First-in-Human Coronary Intervention Study Results of Robocath’s Next-Generation Robotic System Highlighted at TCT https://www.biopharmawatch.com/news/NVNO/envveno-medical-enve-system-tct-symposium BiopharmaWatch en 2026-11-02T13:43:00.000Z enVVeno Medical to Showcase the enVVe System at 38th Annual Transcatheter Cardiovascular Therapeutics (TCT) Scientific Symposium https://www.biopharmawatch.com/news/BEAT/heartbeam-positive-heart-attack-study-results-tct-2026 BiopharmaWatch en 2026-11-02T13:31:00.000Z HeartBeam Announces Positive Heart Attack Pilot Study Results at TCT 2026: Patient-Recorded 3D ECG Shown to Be as Accurate as Standard 12-Lead ECG https://www.biopharmawatch.com/news/LNTH/lantheus-presentation-data-2026-alzheimers-meeting BiopharmaWatch en 2026-11-02T13:30:00.000Z Lantheus Announces Presentation of Data at the 2026 Clinical Trials on Alzheimer’s Disease Annual Meeting https://www.biopharmawatch.com/news/QTI/qt-imaging-third-quarter-2026-results-conference-call BiopharmaWatch en 2026-11-02T13:30:00.000Z QT Imaging to Report Third Quarter 2026 Financial Results and Host Conference Call on November 10, 2026 https://www.biopharmawatch.com/news/GILD/gilead-presents-late-breaking-data-hiv-glasgow BiopharmaWatch en 2026-11-02T13:30:00.000Z Gilead to Present Late-Breaking Clinical Data and Real-World Evidence at HIV Glasgow https://www.biopharmawatch.com/news/DRIO/dariohealth-q3-2026-results-conference-call BiopharmaWatch en 2026-11-02T13:30:00.000Z DarioHealth to Report Third Quarter 2026 Results on Thursday, November 12, 2026 https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-neuro-oncology-research-sno-2026 BiopharmaWatch en 2026-11-02T13:30:00.000Z Jazz Pharmaceuticals to Highlight Neuro-Oncology Clinical Research at SNO 2026 https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-preclinical-data-prp-tgf-beta-inhibitor BiopharmaWatch en 2026-11-02T13:30:00.000Z Propanc Biopharma Reports Preclinical Data with PRP & PRP plus TGF-β Inhibitor on TGF-β Pathway in Pancreatic Cancer https://www.biopharmawatch.com/news/IMNN/imunon-q3-2026-financial-results-conference-call BiopharmaWatch en 2026-11-02T13:30:00.000Z IMUNON to Hold Third Quarter 2026 Financial Results and Business Update Conference Call on Thursday, November 12, 2026 https://www.biopharmawatch.com/news/PRVA/privia-health-acquires-american-choice-healthcare BiopharmaWatch en 2026-11-02T13:30:00.000Z Privia Health Expands VBC Footprint with Acquisition of American Choice Healthcare MSSP Business https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-announces-granting-new-hire-inducement-awards-20261102 BiopharmaWatch en 2026-11-02T13:30:00.000Z Achieve Life Sciences Announces Granting of New Hire Inducement Awards https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-q3-2026-results-call BiopharmaWatch en 2026-11-02T13:30:00.000Z Bicara Therapeutics to Report Third Quarter 2026 Financial Results and Business Updates on November 9, 2026, at 8:30 AM ET https://www.biopharmawatch.com/news/IRON/disc-medicine-participate-upcoming-investor-conferences BiopharmaWatch en 2026-11-02T13:30:00.000Z Disc Medicine to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/HCA/hca-announces-proposed-public-offering-senior-notes-20261102 BiopharmaWatch en 2026-11-02T13:27:00.000Z HCA Announces Proposed Public Offering of Senior Notes https://www.biopharmawatch.com/news/YCBD/cbdmd-acquires-twinlab-assets-expanding-wellness-portfolio BiopharmaWatch en 2026-11-02T13:11:00.000Z cbdMD Completes Acquisition of the Operating Assets and Brands of Twinlab, including Twinlab, Reserveage and Metabolife Brands, Expanding Into Broader Wellness https://www.biopharmawatch.com/news/NNOX/nanox-ai-avc-solution-tct-2026 BiopharmaWatch en 2026-11-02T13:10:00.000Z TCT 2026 Clinical Data Reveals 84% Reporting Gap in Aortic Valve Calcification, Highlighting the Potential of Nanox.AI’s AVC Solution https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-rare-liver-disease-data-aasld-2026 BiopharmaWatch en 2026-11-02T13:02:00.000Z Mirum Pharmaceuticals Showcases Momentum Across Rare Liver Disease Portfolio with New Data at AASLD’s The Liver Meeting® 2026 https://www.biopharmawatch.com/news/NTHI/neonc-technologies-sno-annual-meeting-2026 BiopharmaWatch en 2026-11-02T13:00:37.000Z NeOnc Technologies to Present Data from Its NEO100 and NEO212 Programs at the 31st Annual Meeting of the Society for Neuro-Oncology https://www.biopharmawatch.com/news/TEVA/teva-discontinue-phase-2-topas-msa-study-emrusolmin BiopharmaWatch en 2026-11-02T13:00:00.000Z Teva to Discontinue Phase 2 TOPAS-MSA Study of emrusolmin (TEV-‘286) Following Interim Futility Analysis https://www.biopharmawatch.com/news/XERS/xeris-biopharma-appoints-menassie-taddese-board BiopharmaWatch en 2026-11-02T13:00:00.000Z Xeris Biopharma Welcomes Menassie M. Taddese to Board of Directors https://www.biopharmawatch.com/news/DXCM/dexcom-letter-to-diabetes-campaign BiopharmaWatch en 2026-11-02T13:00:00.000Z Dexcom Invites the Global Diabetes Community to Share Their Stories Through A Letter to Diabetes Campaign https://www.biopharmawatch.com/news/UNH/unitedhealthcare-eases-pediatric-care-access BiopharmaWatch en 2026-11-02T13:00:00.000Z UnitedHealthcare Makes it Easier and Quicker for Children to Get Care for 2,000 Pediatric Care Services https://www.biopharmawatch.com/news/NUVB/nuvation-bio-phase-2-results-sno-meeting-2026 BiopharmaWatch en 2026-11-02T13:00:00.000Z Nuvation Bio to Present Additional Updated Phase 2 Results at 2026 Society for Neuro-Oncology Annual Meeting https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-participate-upcoming-investor-conferences-20261102 BiopharmaWatch en 2026-11-02T13:00:00.000Z PTC Therapeutics to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-atnm-400-sabcs-2026 BiopharmaWatch en 2026-11-02T13:00:00.000Z Actinium Pharmaceuticals Announces Acceptance of ATNM-400 Abstract for Presentation at SABCS 2026 Highlighting Activity Across Therapy-Resistant Breast Cancer Models https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-reports-inducement-grants-permitted-nasdaq-listing-rules-20261102 BiopharmaWatch en 2026-11-02T13:00:00.000Z Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules https://www.biopharmawatch.com/news/MNPR/monopar-aasld-2026-alxn1840-presentation BiopharmaWatch en 2026-11-02T13:00:00.000Z Monopar to Present at AASLD – The Liver Meeting® 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Data https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-november-investor-conferences BiopharmaWatch en 2026-11-02T13:00:00.000Z CytomX Therapeutics to Present at Upcoming November Investor Conferences https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-third-quarter-results-conference-call BiopharmaWatch en 2026-11-02T13:00:00.000Z Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Tuesday, November 10, 2026 https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-appoints-siva-sakhamuri-cto BiopharmaWatch en 2026-11-02T13:00:00.000Z CRISPR Therapeutics Announces the Appointment of Siva Sakhamuri, Ph.D., as Chief Technical Officer https://www.biopharmawatch.com/news/MIST/cardamyst-etripamil-presentation-aha-2026 BiopharmaWatch en 2026-11-02T13:00:00.000Z New Data Presented at AHA Scientific Sessions 2026 Demonstrate That CARDAMYST® (etripamil) Nasal Spray Converted Recurrent PSVT to Normal Heart Rhythm in Patients with Prior Catheter Ablation https://www.biopharmawatch.com/news/HUMA/humacyte-q3-2026-financial-results-update BiopharmaWatch en 2026-11-02T13:00:00.000Z Humacyte To Announce 2026 Third Quarter Financial Results and Provide Business Update on November 10, 2026 https://www.biopharmawatch.com/news/TOVX/theriva-biologics-sale-syn-004-biossil-labs BiopharmaWatch en 2026-11-02T13:00:00.000Z Theriva™ Biologics Announces Sale of SYN-004 (ribaxamase) and Related Antibiotic-Degrading Enzyme Portfolio to Biossil Labs Inc. https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-guggenheim-healthcare-conference BiopharmaWatch en 2026-11-02T13:00:00.000Z Rein Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference https://www.biopharmawatch.com/news/ENLV/enlivex-phase-i-ii-trial-allocetra-data BiopharmaWatch en 2026-11-02T13:00:00.000Z Enlivex Announces Favorable 12-Month Topline Data from Phase I/IIa Allocetra Trial, Demonstrating Durable Treatment Response https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-investor-events-november-2026 BiopharmaWatch en 2026-11-02T13:00:00.000Z Lyell Immunopharma To Participate in November Investor Events https://www.biopharmawatch.com/news/CMMB/chemomab-scipher-merger-sec-registration-effective BiopharmaWatch en 2026-11-02T13:00:00.000Z Chemomab Therapeutics and Scipher Medicine Announce SEC Registration Statement on Form S-4 Is Effective https://www.biopharmawatch.com/news/VERA/vera-therapeutics-guggenheim-healthcare-conference BiopharmaWatch en 2026-11-02T13:00:00.000Z Vera Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference https://www.biopharmawatch.com/news/SION/sionna-therapeutics-november-2026-investor-conferences BiopharmaWatch en 2026-11-02T13:00:00.000Z Sionna Therapeutics to Participate in Upcoming November 2026 Investor Conferences https://www.biopharmawatch.com/news/RADX/radiopharm-theranostics-reports-business-update BiopharmaWatch en 2026-11-02T13:00:00.000Z Radiopharm Theranostics Reports Business Update https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-elraglusib-patent-allowance BiopharmaWatch en 2026-11-02T13:00:00.000Z Actuate Therapeutics Receives U.S. Notice of Allowance for Patent Covering Elraglusib Oral Tablets https://www.biopharmawatch.com/news/URGN/urogen-first-patient-dosed-phase-1-trial-ugn-501 BiopharmaWatch en 2026-11-02T13:00:00.000Z UroGen Announces First Patient Dosed in Phase 1 Trial of UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-new-employee-inducement-grants-nasdaq-listing-rule-20261102 BiopharmaWatch en 2026-11-02T12:46:00.000Z Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-conference-call-q3-2026 BiopharmaWatch en 2026-11-02T12:30:00.000Z TG Therapeutics to Host Conference Call on Third Quarter 2026 Financial Results and Business Update https://www.biopharmawatch.com/news/IMNM/immunome-presentation-guggenheim-healthcare-conference BiopharmaWatch en 2026-11-02T12:30:00.000Z Immunome to Present at Guggenheim 3rd Annual Healthcare Innovation Conference https://www.biopharmawatch.com/news/VSTM/verastem-oncology-november-investor-conferences BiopharmaWatch en 2026-11-02T12:30:00.000Z Verastem Oncology to Participate in Upcoming November Investor Conferences https://www.biopharmawatch.com/news/ARWR/arrowhead-pharmaceuticals-presents-clinical-data-aha-2026 BiopharmaWatch en 2026-11-02T12:30:00.000Z Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026 https://www.biopharmawatch.com/news/DRUG/bright-minds-biosciences-bmb-101-update BiopharmaWatch en 2026-11-02T12:30:00.000Z Bright Minds Biosciences Provides Update About Planned Study with BMB-101 in Developmental and Epileptic Encephalopathies https://www.biopharmawatch.com/news/CRMD/cormedix-business-update-revenue-guidance BiopharmaWatch en 2026-11-02T12:30:00.000Z CorMedix Therapeutics Provides Business Update, Reaffirms 2026 Total Revenue Guidance, and Reports Third Quarter Cash Position https://www.biopharmawatch.com/news/CYTK/cytokinetics-hcms-scientific-sessions-2026 BiopharmaWatch en 2026-11-02T12:30:00.000Z Cytokinetics Announces Three Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026 https://www.biopharmawatch.com/news/RZLT/rezolute-participate-upcoming-investor-conferences BiopharmaWatch en 2026-11-02T12:30:00.000Z Rezolute to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/BWAY/brainsway-collaboration-mindful-health-solutions BiopharmaWatch en 2026-11-02T12:30:00.000Z BrainsWay Announces Strategic Collaboration with Mindful Health Solutions https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-q3-2026-update BiopharmaWatch en 2026-11-02T12:30:00.000Z Cognition Therapeutics to Host Third Quarter 2026 Financial Results and Business Update Call on November 5, 2026 https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-november-investor-conferences BiopharmaWatch en 2026-11-02T12:30:00.000Z Crescent Biopharma to Present at November Investor Conferences https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-q3-2026-financial-results-announcement BiopharmaWatch en 2026-11-02T12:15:00.000Z ADC Therapeutics to Announce Third Quarter 2026 Financial Results on November 9, 2026 https://www.biopharmawatch.com/news/KPTI/karyopharm-merger-ayrmid-future-plans BiopharmaWatch en 2026-11-02T12:10:00.000Z Karyopharm Therapeutics Inc. Announces Planned Merger with Ayrmid Ltd. to Strengthen Company for the Future https://www.biopharmawatch.com/news/QURE/uniqure-fda-acceptance-priority-review-huntingtons-disease BiopharmaWatch en 2026-11-02T12:05:00.000Z uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington’s Disease https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-presentations-november-2026 BiopharmaWatch en 2026-11-02T12:01:00.000Z Lexeo Therapeutics to Present Multiple Oral and Poster Presentations at Key Scientific Conferences in November https://www.biopharmawatch.com/news/YARW/yarrow-bioscience-investor-events-november-2026 BiopharmaWatch en 2026-11-02T12:00:00.000Z Yarrow Bioscience Announces Participation in November Investor Events https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-fda-ind-clearance-epetraborole-pv BiopharmaWatch en 2026-11-02T12:00:00.000Z AN2 Therapeutics Receives U.S. FDA IND Clearance to Proceed with Planned Phase 2 Global Study of Oral Epetraborole in Polycythemia Vera https://www.biopharmawatch.com/news/SPTX/seaport-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-02T12:00:00.000Z Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress https://www.biopharmawatch.com/news/TLRY/tilray-brands-strengthens-canadian-cannabis-operations BiopharmaWatch en 2026-11-02T12:00:00.000Z Tilray Brands Announces Strategy to Strengthen Canadian Cannabis Operations and Drive Profitable Growth https://www.biopharmawatch.com/news/HROW/harrow-launches-harrowrx-platform BiopharmaWatch en 2026-11-02T12:00:00.000Z Harrow Launches HarrowRx Platform https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-q3-2026-results-call BiopharmaWatch en 2026-11-02T12:00:00.000Z Ocular Therapeutix™ to Report Third Quarter 2026 Financial Results on November 9, 2026 https://www.biopharmawatch.com/news/TLSA/tiziana-phase-2a-inform-ms-trial-results BiopharmaWatch en 2026-11-02T12:00:00.000Z Tiziana Announces Positive Topline Results from Phase 2a INFORM-MS Trial of Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis https://www.biopharmawatch.com/news/CLYM/climb-bio-guggenheim-healthcare-conference-2026 BiopharmaWatch en 2026-11-02T12:00:00.000Z Climb Bio to Present at Guggenheim 3rd Annual Healthcare Innovation Conference https://www.biopharmawatch.com/news/RAPP/rapport-closes-public-offerings-stock-notes BiopharmaWatch en 2026-11-02T12:00:00.000Z Rapport Announces Closing of Public Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Notes, as well as Concurrent Private Placement https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-investor-conferences-2026 BiopharmaWatch en 2026-11-02T12:00:00.000Z Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/KRYS/krystal-biotech-q3-2026-results BiopharmaWatch en 2026-11-02T12:00:00.000Z Krystal Biotech Announces Third Quarter 2026 Financial and Operating Results https://www.biopharmawatch.com/news/CBLL/ceribell-launches-delirium-monitoring-solution BiopharmaWatch en 2026-11-02T12:00:00.000Z Ceribell Expands Its Point-of-Care Brain Monitoring Platform with Commercial Launch of Delirium Monitoring Solution https://www.biopharmawatch.com/news/KMDA/kamada-announces-q3-financial-results-call BiopharmaWatch en 2026-11-02T12:00:00.000Z Kamada to Announce Third Quarter and Nine Months Ended September 30, 2026, Financial Results on November 9, 2026 https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-q3-2026-financial-results BiopharmaWatch en 2026-11-02T12:00:00.000Z Axsome Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/ALVO/alvotech-investor-conferences-november-2026 BiopharmaWatch en 2026-11-02T12:00:00.000Z Alvotech to Present at Upcoming Investor Conferences in November https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-appoints-george-lederman BiopharmaWatch en 2026-11-02T12:00:00.000Z Tonix Pharmaceuticals Appoints George Lederman, Ph.D., as Executive Vice President of Strategy and Transformation https://www.biopharmawatch.com/news/KZIA/kazia-paxalisib-abstracts-sabcs-2026 BiopharmaWatch en 2026-11-02T12:00:00.000Z Kazia Therapeutics Announces Two Abstracts on Paxalisib Tumor and Immune Reprogramming Research Accepted for Poster Presentation at 2026 San Antonio Breast Cancer Symposium https://www.biopharmawatch.com/news/CANF/can-fite-eurasian-patent-piclidenoson-lowe-syndrome BiopharmaWatch en 2026-11-02T12:00:00.000Z Can-Fite Announces Eurasian Patent Allowance Supporting Piclidenoson Development and Commercialization in Lowe Syndrome https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-et-900-program-mecasermin BiopharmaWatch en 2026-11-02T11:50:00.000Z Eton Pharmaceuticals Announces Licensing and Initiation of ET-900 Program Evaluating Mecasermin/IGF-1 for Treatment of Infantile and Epileptic Spasms https://www.biopharmawatch.com/news/ACH/accendra-health-receivables-sale-program-extension-2029 BiopharmaWatch en 2026-11-02T11:45:00.000Z Accendra Health Announces Extension of $150 Million Receivables Sale Program To 2029 https://www.biopharmawatch.com/news/MRK/merck-new-data-hiv-glasgow-2026 BiopharmaWatch en 2026-11-02T11:45:00.000Z Merck to Present New Data from Its Broad Oral HIV Portfolio and Pipeline at HIV Glasgow 2026 https://www.biopharmawatch.com/news/AGEN/agenus-unicorn-trial-results-colon-cancer BiopharmaWatch en 2026-11-02T11:42:00.000Z Agenus Announces Nature Medicine Publication of Multicenter UNICORN Phase 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon Cancer https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-third-quarter-results-2026 BiopharmaWatch en 2026-11-02T11:30:00.000Z IDEXX Laboratories Announces Third Quarter Results https://www.biopharmawatch.com/news/CMPS/compass-pathways-trd-survey-report BiopharmaWatch en 2026-11-02T11:30:00.000Z New Joint Survey from Compass Pathways and the Depression and Bipolar Support Alliance Reveals the Lived Burden of Treatment-Resistant Depression on Patients and Caregivers https://www.biopharmawatch.com/news/RNA/atrium-therapeutics-atr-1072-prkag2-syndrome-data-presentation BiopharmaWatch en 2026-11-02T11:30:00.000Z Atrium Therapeutics to Present Nonclinical Data Showing ATR 1072 Reversed and Improved Features of PRKAG2 Syndrome During HCMS at AHA Scientific Sessions 2026 https://www.biopharmawatch.com/news/IMUX/immunic-investor-conferences-november-2026 BiopharmaWatch en 2026-11-02T11:30:00.000Z Immunic to Participate in Investor Conferences in November https://www.biopharmawatch.com/news/GNTA/genenta-rebrands-as-saentra-forge BiopharmaWatch en 2026-11-02T11:00:00.000Z Genenta Unveils Saentra Forge as Its New Brand, Advancing Its Transformation into a Strategic Industrial Platform https://www.biopharmawatch.com/news/OSUR/orasure-joins-world-coalition-sickle-cell-disease BiopharmaWatch en 2026-11-02T10:00:00.000Z OraSure Technologies Joins the World Coalition on Sickle Cell Disease to Advance Access to Earlier Diagnosis and Care https://www.biopharmawatch.com/news/VCRE/vicore-pharma-participate-guggenheim-stifel-conferences BiopharmaWatch en 2026-11-02T07:20:00.000Z Vicore Pharma to Participate in the Guggenheim Annual Healthcare Innovation Conference and the Stifel Healthcare Conference https://www.biopharmawatch.com/blog/biotech-catalysts-to-watch-week-of-2026-11-02 BiopharmaWatch en 2026-11-02T07:16:14.403Z remibetadex NDA for Niemann-Pick Disease: Biotech Catalysts Nov 2, 2026 https://www.biopharmawatch.com/blog/Upcoming_Penny_Stock_Catalysts_in_June_2025_for_Biotech_and_Pharma_-_FDA_Calendar_and_PDUFA_Dates_to_Watch BiopharmaWatch en 2026-11-02T07:15:46.652Z Biotech Penny Stock Catalysts: FDA Calendar and PDUFA Dates for Small-Cap Pharma Stocks https://www.biopharmawatch.com/news/OCS/oculis-appoints-bjorn-tackenberg-cso-advance-neurology-innovation BiopharmaWatch en 2026-11-02T07:00:00.000Z Oculis Appoints Experienced Life Sciences Leader Björn Tackenberg, M.D., Ph.D., as Chief Scientific Officer to Advance Neurology Innovation https://www.biopharmawatch.com/news/HCM/hutchmed-orpathys-tagrisso-regulatory-filings-europe-japan BiopharmaWatch en 2026-11-02T00:00:00.000Z HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan https://www.biopharmawatch.com/news/MESO/mesoblast-board-changes-november-2026 BiopharmaWatch en 2026-11-01T23:46:00.000Z Mesoblast Board Changes https://www.biopharmawatch.com/news/AVR/anteris-reports-duravr-thv-outcomes-embark-study BiopharmaWatch en 2026-11-01T19:59:00.000Z Anteris Reports Medium-Size DurAVR THV Outcomes from the EMBARK Study at TCT 2026 https://www.biopharmawatch.com/news/HTFL/ct-guided-pci-matches-ivus-outcomes-tct-2026 BiopharmaWatch en 2026-11-01T18:45:00.000Z TCT 2026: CT-guided PCI Matches IVUS Outcomes in Randomized P4 Trial; Heartflow PCI Navigator Changes PCI Plans in Approximately 70% of Patients https://www.biopharmawatch.com/news/GEHC/ge-healthcare-allia-celeo-launch-tct-2026 BiopharmaWatch en 2026-11-01T17:35:00.000Z GE HealthCare debuts Allia Celeo, a ceiling-mounted interventional system designed for smooth procedural flow and AI-powered precision imaging https://www.biopharmawatch.com/news/ABT/abbott-tectonic-trial-sonicforce-results BiopharmaWatch en 2026-11-01T00:00:00.000Z Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System